We’re proud to announce that NunaBio has been shortlisted for two CPHI Awards in 2025 – Start-up Initiative and Accelerating Innovation.
This recognition is especially significant as the CPHI Awards are among the most prestigious in the pharmaceutical and biotechnology sector. Each year, they highlight the companies and individuals making the biggest impact on the future of healthcare and innovation. To be named a finalist in two categories reflects both the strength of our technology and the commitment of our team to transforming DNA synthesis.
The Start-up Initiative category celebrates emerging companies with the potential to reshape the industry, while Accelerating Innovation recognises breakthroughs that push the boundaries of science and technology. Being shortlisted in both underlines NunaBio’s dual focus: building a next-generation company while also driving forward technological innovation that can change how DNA is made and used across research, therapeutics, and beyond.
We extend our congratulations to all of the other shortlisted candidates and wish them the best of luck.
Stay tuned as we head into CPHI – we look forward to sharing more updates from the event!
